Table 5 The comparative analysis of PRMT1, ZEB1, RUNX1 and TWIST1 immunopositivity with clinic-pathological features of the patients with ccRCC
PRMT1 | p-value | ZEB1 | p-value | RUNX | p-value | TWIST1 | p-value | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
+ | – | + | – | + | – | + | – | |||||
Grade | ||||||||||||
I/II | 62 (68.8) | 28 (31.2) | 0.009* | 38 (35.7) | 54 (64.3) | 0.093 | 51 (59.3) | 35 (40.7) | 0.846 | 84 (97.7) | 2 (2.3) | 1 |
III/IV | 13 (41.9) | 18 (58.1) | 6 (19.4) | 25 (80.6) | 19 (61.3) | 12 (38.7) | 30 (96.8) | 1 (3.2) | ||||
Stage | ||||||||||||
pT1/pT2 | 49 (69.0) | 22 (31.0) | 0.046* | 23 (34.3) | 44 (65.7) | 0.409 | 37 (54.4) | 31 (45.6) | 0.159 | 67 (97.1) | 2 (2.9) | |
pT3/pT4 | 25 (51.0) | 24 (49.0) | 13 (27.1) | 35 (72.9) | 33 (67.3) | 16 (32.7) | 47 (97.9) | 1 (2.9) | 1 | |||
Gender | ||||||||||||
Male | 44 (55.7) | 35 (44.3) | 0.110 | 23 (30.7) | 52 (69.3) | 0.509 | 46 (60.5) | 30 (39.5) | 0.834 | 76 (98.8) | 1 (1.2) | 0.276 |
Female | 29 (70.7) | 12 (29.3) | 14 (36.8) | 24 (63.2) | 24 (58.5) | 17 (41.5) | 39 (95.1) | 2 (4.9) | ||||
Age, mean ± SD (years) | 61 ± 9.45 | 62.6 ± 8.38 | 0.346 | 63 ± 8.75 | 61.2 ± 9 | 0.378 | 62 ± 8.9 | 61 ± 8.7 | 0.704 | 61.9 ± 8.8 | 59 ± 5.03 | 0.536 |
Tumour size, mean ± SD (mm) | 67 ± 48.75 | 74.5 ± 32.3 | 0.362 | 63 ± 35.1 | 74.1 ± 45.7 | 0.181 | 70 ± 50 | 71.7 ± 32.8 | 0.830 | 70.6 ± 43.7 | 65 ± 18.03 | 0.823 |